


5640



RAW SEQUENCE LISTING **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/787,436
Source: PCR/09
Date Processed by STIC: 4/21/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

<http://www.uspto.gov/web/offices/pac/checker>

PCT

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/787,436

DATE: 04/21/2001
TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

ppr 1-5
**Does Not Comply
Corrected Diskette Needed**

do not insert <110> at beginning of each applicant here

1 <110> APPLICANT: DELANSORNE, R,mi
W--> 2 ~~<110> APPLICANT: BONNET, Paule~~
W--> 3 ~~<110> APPLICANT: PARIS, Jacques~~
4 <120> TITLE OF INVENTION: Pharmaceutical compositions based on alpha-cyclodextrin
5 for the oral administration of LH-RH analogues
6 <130> FILE REFERENCE: H20058-5US
7 <140> CURRENT APPLICATION NUMBER: US/09/787,436
8 <141> CURRENT FILING DATE: 2000-03-17
9 <150> PRIOR APPLICATION NUMBER: PCT/EP99/07389
10 <151> PRIOR FILING DATE: 1999-09-23
11 <150> PRIOR APPLICATION NUMBER: EP98402403.4
12 <151> PRIOR FILING DATE: 1998-09-30
13 <160> NUMBER OF SEQ ID NOS: 7
14 <170> SOFTWARE: PatentIn Ver. 2.1
16 <210> SEQ ID NO: 1
17 <211> LENGTH: 10
18 <212> TYPE: PRT
19 <213> ORGANISM: Artificial Sequence
20 <220> FEATURE:
21 <223> OTHER INFORMATION: Description of Artificial Sequence: LH-RH analogue
22 <221> NAME/KEY: SITE
23 <222> LOCATION: (1)
24 <223> OTHER INFORMATION: Xaa is pGlu, D-pGlu, Sar, AcSar, Pro, Ser, D-Ser, Ac-D-Ser,
25 Thr, D-Thr, Ac-D-Thr or an optionally substituted and/or acylated
26 aromatic D-amino acid
27 <221> NAME/KEY: SITE
28 <222> LOCATION: (2)
29 <223> OTHER INFORMATION: Xaa His or an optionally substituted aromatic D-amino acid
30 <221> NAME/KEY: SITE
31 <222> LOCATION: (3)
32 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L- or D-amino acid
33 <221> NAME/KEY: SITE
34 <222> LOCATION: (4)
35 <223> OTHER INFORMATION: Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBut), Ser(OBzl) or Thr
36 <221> NAME/KEY: SITE
37 <222> LOCATION: (5)
38 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
39 or an optionally substituted basic L- or D-amino acid
40 <221> NAME/KEY: SITE
41 <222> LOCATION: (6)
42 <223> OTHER INFORMATION: Xaa is Gly, (S)-spiro lactam-Pro, D-Pro, D-Ser, D-Thr,
43 D-Cys, D-Met, D-Asn, D-Pen, D-(S-Me)Pen, D-(S-Et)Pen,
44 D-Ser(OBut), D-Asp(OBut), D-Glu(OBut), D-Thr(OBut),
45 D-Cys(OBut), D-Ser(OR1) where R1 is a sugar moiety, an
W--> 46 <223> aza-amino acid, D-His which may be substituted on the
W--> 47 <223> imidazole ring by a (C1-C6)alkyl, a (C2-C7)acyl or a
W--> 48 <223> benzyl group, an aliphatic D-amino acid with a (C1-C8)-

Per 1.823 of new Sequence Rules, <223> responses have a MAXIMUM of 4 lines. Do not exceed. If response is more than 4 lines, add <220>, and new <223>

4/21/01

RAW SEQUENCE LISTING

DATE: 04/21/2001

PATENT APPLICATION: US/09/787,436

TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw

Output Set: N:\CRF3\04202001\I787436.raw

W--> 49 223 alkyl or a (C3-C6)cycloalkyl side chain, an optionally -> 2207
W--> 50 223 substituted aromatic D-amino acid, D-cyclohexadienyl-Gly,
W--> 51 223 D-perhydronaphthyl-Ala, D-perhydrodiphenyl-Ala or an
W--> 52 223 optionally substituted basic L- or D-amino acid
53 <221> NAME/KEY: SITE
54 <222> LOCATION: (7)
55 <223> OTHER INFORMATION: Xaa is a linear, branched or cyclic aliphatic L-amino
56 acid of 3 to 20 carbon atoms which may be N-alpha-
57 substituted by a (C1-C4)alkyl group optionally substituted
58 by one or several fluorine atoms
59 <221> NAME/KEY: SITE
60 <222> LOCATION: (8)
61 <223> OTHER INFORMATION: Xaa is an optionally substituted basic L- or D-amino acid
62 <221> NAME/KEY: SITE
63 <222> LOCATION: (10)
64 <223> OTHER INFORMATION: Xaa is GlyNH2, D-AlaNH2, azaGlyNH2 or a group -NHR2
65 where R2 is a (C1-C4)alkyl which may be substituted by
66 an hydroxy or one or several fluorine atoms, a (C3-
67 C6)cycloalkyl or a heterocyclic radical selected from -> 2207
W--> 68 223 morpholinyl, pyrrolidinyl and piperidyl
69 <400> SEQUENCE: 1
W--> 70 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
71 1 5 10
73 <210> SEQ ID NO: 2
74 <211> LENGTH: 10
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Description of Artificial Sequence: LH-RH analogue
79 <221> NAME/KEY: SITE
80 <222> LOCATION: (1)
81 <223> OTHER INFORMATION: Xaa is pGlu, Sar or AcSar
82 <221> NAME/KEY: SITE
83 <222> LOCATION: (3)
84 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
85 <221> NAME/KEY: SITE
86 <222> LOCATION: (4)
87 <223> OTHER INFORMATION: Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBut), Ser(OBzl) or Thr
88 <221> NAME/KEY: SITE
89 <222> LOCATION: (5)
90 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
91 <221> NAME/KEY: SITE
92 <222> LOCATION: (6)
93 <223> OTHER INFORMATION: Xaa is Gly, (S)-spiro lactam-Pro, D-Pro, D-Ser, D-Thr,
94 D-Cys, D-Met, D-Pen, D-(S-Me)Pen, D-(S-Et)Pen,
95 D-Ser(OBut), D-Asp(OBut), D-Glu(OBut), D-Thr(OBut),
96 D-Cys(OBut), D-Ser(OR1) where R1 is a sugar moiety, an -> 2207
W--> 97 223 aza-amino acid, D-His which may be substituted on the
W--> 98 223 imidazole ring by a (C1-C6)alkyl or a benzyl group, an

FYI: Xaa
can only

represent a
single amino
acid, nothing
else

RAW SEQUENCE LISTING

DATE: 04/21/2001

PATENT APPLICATION: US/09/787,436

TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw

Output Set: N:\CRF3\04202001\I787436.raw

W--> 99 <223> aliphatic D-amino acid with a (C1-C8)alkyl or a (C3-
W--> 100 <223> C6)cycloalkyl side chain, an optionally substituted
W--> 101 <223> aromatic D-amino acid, D-cyclohexadienyl-Gly, D-
W--> 102 <223> perhydronaphthyl-Ala, D-perhydrodiphenyl-Ala or an
W--> 103 <223> optionally substituted basic D-amino acid
104 <221> NAME/KEY: SITE
105 <222> LOCATION: (7)
106 <223> OTHER INFORMATION: Xaa is a linear, branched or cyclic aliphatic L-amino
107 acid of 3 to 20 carbon atoms which may be N-alpha-
108 substituted by a (C1-C4)alkyl group optionally substituted
109 by one or several fluorine atoms
110 <221> NAME/KEY: SITE
111 <222> LOCATION: (8)
112 <223> OTHER INFORMATION: Xaa is an optionally substituted basic L-amino acid
113 <221> NAME/KEY: SITE
114 <222> LOCATION: (10)
115 <223> OTHER INFORMATION: Xaa is GlyNH2, azaGlyNH2 or a group -NHR2 where R2 is
116 a (C1-C4)alkyl which may be substituted by an hydroxy
117 or one or several fluorine atoms, a (C3-C6)cycloalkyl
118 or a heterocyclic radical selected from morpholinyl,
W--> 119 <223> pyrrolidinyl and piperidyl
120 <400> SEQUENCE: 2
W--> 121 Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
122 1 5 10
124 <210> SEQ ID NO: 3
125 <211> LENGTH: 10
126 <212> TYPE: PRT
127 <213> ORGANISM: Artificial Sequence
128 <220> FEATURE:
129 <223> OTHER INFORMATION: Description of Artificial Sequence: LH-RH analogue
130 <221> NAME/KEY: SITE
131 <222> LOCATION: (1)
132 <223> OTHER INFORMATION: Xaa is pGlu
133 <221> NAME/KEY: SITE
134 <222> LOCATION: (3)
135 <223> OTHER INFORMATION: Xaa is as defined for SEQ ID NO:2
136 <221> NAME/KEY: SITE
137 <222> LOCATION: (5)
138 <223> OTHER INFORMATION: Xaa is as defined for SEQ ID NO:2
139 <221> NAME/KEY: SITE
140 <222> LOCATION: (6)
141 <223> OTHER INFORMATION: Xaa is as defined for SEQ ID NO:2
142 <221> NAME/KEY: SITE
143 <222> LOCATION: (7)
144 <223> OTHER INFORMATION: Xaa is Leu, Ile, Nle, Hol, Npg, Cha or Ada, which may
145 be N-alpha-substituted by a methyl or ethyl group
146 optionally substituted by one or several fluorine atoms
147 <221> NAME/KEY: SITE
148 <222> LOCATION: (10)

> <220>

> <220>

*FYI! Xaa
can only
represent
a single
amino acid*

RAW SEQUENCE LISTING

DATE: 04/21/2001

PATENT APPLICATION: US/09/787,436

TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw

Output Set: N:\CRF3\04202001\I787436.raw

149 <223> OTHER INFORMATION: Xaa is as defined for SEQ ID NO:2
 150 <400> SEQUENCE: 3
 W--> 151 Xaa His Xaa Ser Xaa Xaa Xaa Arg Pro Xaa
 152 1 5 10
 154 <210> SEQ ID NO: 4
 155 <211> LENGTH: 10
 156 <212> TYPE: PRT
 157 <213> ORGANISM: Artificial Sequence
 158 <220> FEATURE:
 159 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
 160 <221> NAME/KEY: SITE
 161 <222> LOCATION: (1)
 162 <223> OTHER INFORMATION: Xaa is pGlu
 163 <221> NAME/KEY: SITE
 164 <222> LOCATION: (3)
 165 <223> OTHER INFORMATION: Xaa is Phe, Tyr, Trp, 2MeTrp, HPhe, HTyr, Nal, lNal,
 166 Bal, Pal, 4Pal or pClPhe
 167 <221> NAME/KEY: SITE
 168 <222> LOCATION: (5)
 169 <223> OTHER INFORMATION: Xaa is Phe, Tyr, Trp, 2MeTrp, HPhe, HTyr, Nal, lNal,
 170 Bal, Pal, 4Pal or pClPhe
 171 <221> NAME/KEY: SITE
 172 <222> LOCATION: (6)
 173 <223> OTHER INFORMATION: Xaa is (S)-spiro lactam-Pro, Gly, D-Pro, D-Ser(OBut),
 174 D-Asp(OBut), D-Glu(OBut), D-Thr(OBut), D-Cys(OBut),
 175 D-His, D-His(Bzl), D-Ala, D-Leu, D-Tle, D-Nle, D-Hol,
 176 D-Npg, D-Cha, D-Phe, D-HPhe, D-Tyr, D-HTyr, D-Trp, -> 2207
 W--> 177 2237 D-2MeTrp, D-Nal, D-lNal, D-Bal, D-Pal, D-4Pal, D-pClPhe
 W--> 178 2237 D-cyclohexadienyl-Gly, D-perhydronaphtyl-Ala,
 W--> 179 2237 D-perhydrodiphenyl-Ala or D-APhe optionally substituted
 W--> 180 2237 by an aminotriazolyl group
 181 <221> NAME/KEY: SITE
 182 <222> LOCATION: (7)
 183 <223> OTHER INFORMATION: Xaa is Leu, Npg or Cha, which may be N-alpha-substituted
 184 by a methyl group
 185 <221> NAME/KEY: SITE
 186 <222> LOCATION: (10)
 187 <223> OTHER INFORMATION: Xaa is GlyNH2, azaGlyNH2 or -NC2H5
 188 <400> SEQUENCE: 4
 W--> 189 Xaa His Xaa Ser Xaa Xaa Xaa Arg Pro Xaa
 190 1 5 10
 192 <210> SEQ ID NO: 5
 193 <211> LENGTH: 10
 194 <212> TYPE: PRT
 195 <213> ORGANISM: Artificial Sequence
 196 <220> FEATURE:
 197 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
 198 <221> NAME/KEY: SITE
 199 <222> LOCATION: (1)

RAW SEQUENCE LISTING

DATE: 04/21/2001

PATENT APPLICATION: US/09/787,436

TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw

Output Set: N:\CRF3\04202001\I787436.raw

200 <223> OTHER INFORMATION: Xaa is pGlu
 201 <221> NAME/KEY: SITE
 202 <222> LOCATION: (6)
 203 <223> OTHER INFORMATION: Xaa is (S)-spirolactam-Pro, D-Leu, D-Ala, D-Nal,
 204 D-Phe, D-Ser(Obut) or D-Trp
 205 <221> NAME/KEY: SITE
 206 <222> LOCATION: (7)
 207 <223> OTHER INFORMATION: Xaa is Leu, MeLeu, Npg or MeNpg
 208 <221> NAME/KEY: SITE
 209 <222> LOCATION: (10)
 210 <223> OTHER INFORMATION: Xaa is GlyNH2, azaGlyNH2 or -NC2H5
 211 <400> SEQUENCE: 5
 W--> 212 Xaa His Trp Ser Tyr Xaa Xaa Arg Pro Xaa
 213 1 5 10
 215 <210> SEQ ID NO: 6
 216 <211> LENGTH: 10
 217 <212> TYPE: PRT
 218 <213> ORGANISM: Artificial Sequence
 219 <220> FEATURE:
 220 <223> OTHER INFORMATION: Description of Artificial Sequence: LH-RH analogue
 221 <221> NAME/KEY: SITE
 222 <222> LOCATION: (1)
 223 <223> OTHER INFORMATION: Xaa is pGlu, D-pGlu, Sar, AcSar, Pro thereof, Ser, D-Ser,
 224 Ac-D-Ser, Thr, D-Thr, Ac-D-Thr or an optionally substituted
 225 and/or acylated aromatic D-amino acid
 226 <221> NAME/KEY: SITE
 227 <222> LOCATION: (2)
 228 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic D-amino acid
 229 <221> NAME/KEY: SITE
 230 <222> LOCATION: (3)
 231 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L- or D-amino acid
 232 <221> NAME/KEY: SITE
 233 <222> LOCATION: (4)
 234 <223> OTHER INFORMATION: Xaa is Ala, Ser, D-Ser, MeSer, Ser(Obut), Ser(Obzl) or Thr
 235 <221> NAME/KEY: SITE
 236 <222> LOCATION: (5)
 237 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
 238 or an optionally substituted basic L- or D-amino acid
 239 <221> NAME/KEY: SITE
 240 <222> LOCATION: (6)
 241 <223> OTHER INFORMATION: Xaa is Gly, (S)-spirolactam-Pro, D-Pro, D-Ser, D-Thr,
 242 D-Cys, D-Met, D-Asn, D-Pen, D-(S-Me)Pen, D-(S-Et)Pen,
 243 D-Ser(Obut), D-Asp(Obut), D-Glu(O-But), D-Thr(O-But),
 244 D-Cys(O-But), D-Ser(O-R1) where R1 is a sugar moiety, ><220>
 W--> 245 <223> an aliphatic D-amino acid with a (C1-C8)alkyl or a
 W--> 246 <223> (C3-C6)cycloalkyl side chain, an optionally substituted
 W--> 247 <223> aromatic D-amino acid, D-cyclohexadienyl-Gly, D-
 W--> 248 <223> perhydropnaphthyl-Ala, D-perhydrodiphenyl-Ala or an
 W--> 249 <223> optionally substituted basic L- or D-amino acid ><220>

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY

DATE: 04/21/2001

PATENT APPLICATION: US/09/787,436

TIME: 21:31:44

Input Set : N:\Crf3\04042001\I787436.raw

Output Set: N:\CRF3\04202001\I787436.raw

L:2 M:280 W: Numeric Identifier already exists, <110> found multiple times
L:3 M:280 W: Numeric Identifier already exists, <110> found multiple times
L:46 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:47 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:48 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:49 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:50 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:51 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:52 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:68 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:70 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:97 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:98 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:99 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:100 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:101 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:102 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:103 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:119 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:121 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:151 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:177 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:178 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:179 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:180 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:212 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:245 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:246 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:247 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:248 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:249 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:263 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:298 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7